Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome / 대한내과학회지
Korean Journal of Medicine
;
: 496-500, 2014.
Article
Dans Coréen
| WPRIM
| ID: wpr-176486
ABSTRACT
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78-year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient's subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Épanchement pleural
/
Pneumopathie infectieuse
/
Azacitidine
/
Syndromes myélodysplasiques
/
Diagnostic
/
Traitement médicamenteux
/
Dyspnée
/
Lésion pulmonaire
/
Fièvre
/
Antibactériens
Type d'étude:
Essai clinique contrôlé
/
Etude diagnostique
Limites du sujet:
Adulte très âgé
/
Humains
/
Mâle
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS